C-reactive protein is related to future cognitive impairment and decline in elderly individuals with cardiovascular disease

Archives of Gerontology and Geriatrics

Volumn 69, Issue , 2017, Pages 31-37

  Weinstein, Galit ^a   Lutski, Miriam ^b   Goldbourt, Uri ^b   Tanne, David ^b,c  

^a UNIVERSITY OF HAIFA   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

C reactive protein; Cardiovascular disease; Cognition; Cognitive decline; Elderly; Inflammation

Indexed keywords

BEZAFIBRATE; C REACTIVE PROTEIN; FIBRINOGEN; ANTILIPEMIC AGENT; BIOLOGICAL MARKER;

AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; ATTENTION; BLOOD VESSEL TONE; BODY MASS; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; HEART MUSCLE CONTRACTILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CONTRACTILITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING; SYSTOLIC BLOOD PRESSURE; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COGNITION; COGNITIVE DYSFUNCTION; COMPLICATION; DOSE RESPONSE; EPIDEMIOLOGY; INFLAMMATION; ISRAEL; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PREVALENCE;

AGED; ATTENTION; BEZAFIBRATE; BIOMARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; COGNITION; COGNITIVE DYSFUNCTION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; INFLAMMATION; ISRAEL; MALE; MIDDLE AGED; PREVALENCE;

EID: 84996615405     PISSN: 01674943     EISSN: 18726976     Source Type: Journal    
DOI: 10.1016/j.archger.2016.11.002     Document Type: Article

References (49)

1. Albert, S.M., Glied, S., Andrews, H., Stern, Y., Mayeux, R., Primary care expenditures before the onset of Alzheimer's disease. Neurology 59 (2002), 573–578.
2. American Psychiatric Association, Diagnostic and statistical manual of mental disorders. 4th ed., 1994, American Psychiatric Association, Washington DC.
3. Arfanakis, K., Fleischman, D.A., Grisot, G., et al. Systemic inflammation in non-demented elderly human subjects: Brain microstructure and cognition. PLoS One, 8, 2013, e73107.
4. Butchart, J., Birch, B., Bassily, R., Wolfe, L., Holmes, C., Male sex hormones and systemic inflammation in Alzheimer disease. Alzheimer Disease and Associated Disorders 27 (2013), 153–156.
5. Casserly, I., Topol, E., Convergence of atherosclerosis and Alzheimer's disease: Inflammation, cholesterol, and misfolded proteins. Lancet 363 (2004), 1139–1146.
6. Duong, T., Nikolaeva, M., Acton, P.J., C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer's disease. Brain Research 749 (1997), 152–156.
7. Dwolatzky, T., Whitehead, V., Doniger, G.M., et al. Validity of a novel computerized cognitive battery for mild cognitive impairment. BMC Geriatrics, 3, 2003, 4.
8. Eikelenboom, P., van Exel, E., Hoozemans, J.J., Veerhuis, R., Rozemuller, A.J., van Gool, W.A., Neuroinflammation – an early event in both the history and pathogenesis of Alzheimer's disease. Neurodegenerative Disease 7 (2010), 38–41.
9. Elias, M.F., Beiser, A., Wolf, P.A., Au, R., White, R.F., D'Agostino, R.B., The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort. Archives of Neurology 57 (2000), 808–813.
10. Engelhart, M.J., Geerlings, M.I., Meijer, J., et al. Inflammatory proteins in plasma and the risk of dementia: The rotterdam study. Archives of Neurology 61 (2004), 668–672.
11. Fornage, M., Chiang, Y.A., O'Meara, E.S., et al. Biomarkers of inflammation and MRI-defined small vessel disease of the brain: The cardiovascular health study. Stroke 39 (2008), 1952–1959.
12. Gorelick, P.B., Role of inflammation in cognitive impairment: Results of observational epidemiological studies and clinical trials. Annals of the New York Academy of Sciences 1207 (2010), 155–162.
13. Gunstad, J., Bausserman, L., Paul, R.H., et al. C-reactive protein, but not homocysteine, is related to cognitive dysfunction in older adults with cardiovascular disease. Journal of Clinical Neuroscience 13 (2006), 540–546.
14. Hatano, S., Experience from a multicentre stroke register: A preliminary report. Bulletin of the World Health Organization 54 (1976), 541–553.
15. Heneka, M.T., Carson, M.J., El Khoury, J., et al. Neuroinflammation in alzheimer's disease. Lancet Neurology 14 (2015), 388–405.
16. Hoth, K.F., Haley, A.P., Gunstad, J., et al. Elevated C-reactive protein is related to cognitive decline in older adults with cardiovascular disease. Journal of the American Geriatrics Society 56 (2008), 1898–1903.
17. Iwamoto, N., Nishiyama, E., Ohwada, J., Arai, H., Demonstration of CRP immunoreactivity in brains of Alzheimer's disease: Immunohistochemical study using formic acid pretreatment of tissue sections. Neuroscience Letters 177 (1994), 23–26.
18. Jefferson, A.L., Massaro, J.M., Wolf, P.A., et al. Inflammatory biomarkers are associated with total brain volume: The Framingham Heart Study. Neurology 68 (2007), 1032–1038.
19. Jefferson, A.L., Massaro, J.M., Beiser, A.S., et al. Inflammatory markers and neuropsychological functioning: The Framingham Heart Study. Neuroepidemiology 37 (2011), 21–30.
20. Kaptoge, S., Di Angelantonio, E., Lowe, G., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. Lancet 375 (2010), 132–140.
21. Koyama, A., O'Brien, J., Weuve, J., Blacker, D., Metti, A.L., Yaffe, K., The role of peripheral inflammatory markers in dementia and Alzheimer's disease: A meta-analysis. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 68 (2013), 433–440.
22. Li, R., Singh, M., Sex differences in cognitive impairment and Alzheimer's disease. Frontiers in Neuroendocrinology 35 (2014), 385–403.
23. Libby, P., Inflammation in atherosclerosis. Nature 420 (2002), 868–874.
24. Luciano, M., Marioni, R.E., Gow, A.J., Starr, J.M., Deary, I.J., Reverse causation in the association between C-reactive protein and fibrinogen levels and cognitive abilities in an aging sample. Psychosomatic Medicine 71 (2009), 404–409.
25. Lyketsos, C.G., Lopez, O., Jones, B., Fitzpatrick, A.L., Breitner, J., DeKosky, S., Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. JAMA 288 (2002), 1475–1483.
26. Marioni, R.E., Stewart, M.C., Murray, G.D., et al. Peripheral levels of fibrinogen, C-reactive protein, and plasma viscosity predict future cognitive decline in individuals without dementia. Psychosomatic Medicine 71 (2009), 901–906.
27. McCarrey, A.C., An, Y., Kitner-Triolo, M.H., Ferrucci, L., Resnick, S.M., Sex differences in cognitive trajectories in clinically normal older adults. Psychology and Aging 31:2 (2016), 166–175.
28. Muller, M., Voges, M., Piepgras, U., Schimrigk, K., Assessment of cerebral vasomotor reactivity by transcranial Doppler ultrasound and breath-holding. A comparison with acetazolamide as vasodilatory stimulus. Stroke; A Journal of Cerebral Circulation 26 (1995), 96–100.
29. Muller, M., Grobbee, D.E., Aleman, A., Bots, M., van der Schouw, Y.T., Cardiovascular disease and cognitive performance in middle-aged and elderly men. Atherosclerosis 190 (2007), 143–149.
30. Petersen, R.C., Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine 256 (2004), 183–194.
31. Plassman, B.L., Langa, K.M., Fisher, G.G., et al. Prevalence of cognitive impairment without dementia in the United States. Annals of Internal Medicine 148 (2008), 427–434.
32. Roman, G.C., Erkinjuntti, T., Wallin, A., Pantoni, L., Chui, H.C., Subcortical ischaemic vascular dementia. Lancet Neurology 1 (2002), 426–436.
33. Ross, R., Atherosclerosis – an inflammatory disease. New England Journal of Medicine 340 (1999), 115–126.
34. Sabayan, B., Jansen, S., Oleksik, A.M., et al. Cerebrovascular hemodynamics in Alzheimer's disease and vascular dementia: A meta-analysis of transcranial Doppler studies. Ageing Research Reviews 11 (2012), 271–277.
35. Satizabal, C.L., Zhu, Y.C., Mazoyer, B., Dufouil, C., Tzourio, C., Circulating IL-6 and CRP are associated with MRI findings in the elderly: The 3C-Dijon Study. Neurology 78 (2012), 720–727.
36. Schmidt, R., Schmidt, H., Curb, J.D., Masaki, K., White, L.R., Launer, L.J., Early inflammation and dementia: A 25-year follow-up of the Honolulu-Asia Aging Study. Annals of Neurology 52 (2002), 168–174.
37. Schram, M.T., Euser, S.M., de Craen, A.J., et al. Systemic markers of inflammation and cognitive decline in old age. Journal of the American Geriatrics Society 55 (2007), 708–716.
38. Scirica, B.M., Morrow, D.A., Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 113 (2006), 2128–2134 [discussion 51].
39. Secondary Prevention, Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation 102 (2000), 21–27.
40. Seshadri, S., Wolf, P.A., Lifetime risk of stroke and dementia: Current concepts, and estimates from the Framingham Study. The Lancet Neurology 6 (2007), 1106–1114.
41. Silbert, B., Evered, L., Scott, D.A., McCutcheon, C., Jamrozik, K., Homocysteine and C-reactive protein are not markers of cognitive impairment in patients with major cardiovascular disease. Dementia and Geriatric Cognitive Disorders 25 (2008), 309–316.
42. Singh-Manoux, A., Britton, A.R., Marmot, M., Vascular disease and cognitive function: Evidence from the Whitehall II Study. Journal of the American Geriatrics Society 51 (2003), 1445–1450.
43. Singh-Manoux, A., Sabia, S., Lajnef, M., et al. History of coronary heart disease and cognitive performance in midlife: The Whitehall II study. European Heart Journal 29 (2008), 2100–2107.
44. Tabert, M.H., Albert, S.M., Borukhova-Milov, L., et al. Functional deficits in patients with mild cognitive impairment: Prediction of AD. Neurology 58 (2002), 758–764.
45. Tanne, D., Benderly, M., Goldbourt, U., et al. C-reactive protein as a predictor of incident ischemic stroke among patients with preexisting cardiovascular disease. Stroke 37 (2006), 1720–1724.
46. Trollor, J.N., Smith, E., Baune, B.T., et al. Systemic inflammation is associated with MCI and its subtypes: The Sydney Memory and Aging Study. Dementia and Geriatric Cognitive Disorders 30 (2010), 569–578.
47. Verma, S., Devaraj, S., Jialal, I., Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 113 (2006), 2135–2150 [discussion 50].
48. Weuve, J., Ridker, P.M., Cook, N.R., Buring, J.E., Grodstein, F., High-sensitivity C-reactive protein and cognitive function in older women. Epidemiology 17 (2006), 183–189.
49. Yaffe, K., Lindquist, K., Penninx, B.W., et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 61 (2003), 76–80.